What is the rationale for novel combination therapies?
Niels van de Donk
Advancing cellular therapies for blood cancers
T-cell therapy: successes and unmet needs
Ibrutinib in treatment for refractory or relapsed CLL
Current therapy for CLL and the new monoclonal antibody ofatumumab